CMTA Strategy to Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, its investigational antisense oligonucleotide (ASO) therapy for Charcot-Marie-Tooth disease type 2S (CMT2S).
Rare Pediatric Disease Designation is intended to encourage the development of therapies for serious diseases that primarily affect children. The designation may provide certain development and regulatory incentives but does not indicate that a therapy has been shown to be safe or effective.
What this means for patients and families
For families living with CMT2S, options today are mostly limited to supportive care, physical therapy, and symptom management. The disease typically progresses, undermining mobility and independence over time. A therapy like VCA894A, even if initially developed for a single patient, offers proof-of-concept that genetic “fixes” can be customized to specific mutations in ultrarare conditions. That could open the door to similar approaches for other children with unique variants, provided safety, effectiveness, and regulatory pathways can be worked out.
Why the FDA’s designation is important
The FDA grants Rare Pediatric Disease Designation to encourage new treatments for serious or life-threatening conditions that primarily affect children and are very uncommon in the general population. For VCA894A, the agency recognized that CMT2S is both extremely rare and severely impacts pediatric patients, and that there are essentially no targeted therapies available today.
If VCA894A ultimately wins FDA approval and meets all program criteria, Vanda could receive a transferable priority review voucher. That voucher can be used to speed the review of another drug or sold to another company. The designation itself does not guarantee approval or a voucher, but it indicates that regulators view the condition as a high-need pediatric disease.
What you can do now
The study, led by Vanda Pharmaceuticals, is seeking people with CMT2S caused by a specific IGHMBP2 gene mutation that VCA-894A is designed to target. The information collected will help researchers identify potentially eligible participants and advance research into this investigational therapy. Every participant also helps researchers better understand CMT2S.
If you or a family member has CMT2S, you can help advance research by joining CMTA’s Patients as Partners in Research. Once you’re registered, you’ll learn more about the CMT2S Research Study and determine whether you may be eligible to participate.
Read Vanda Pharmaceuticals’ full announcement.
